Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 13/20 | 0.35 |
| ▸ | ATR | Q13535 | 2/20 | 0.34 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.33 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.32 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26998274 | 0.88 | ROCK2 (0.33) | ROCK2ATRATRIPROCK1 | |
| SCHEMBL26998273 | 0.86 | ROCK2 (0.36) | ROCK2MAP4K4ROCK1 | |
| SCHEMBL26998669 | 0.85 | ROCK2 (0.37) | ROCK2ATRATRIPROCK1 | |
| SCHEMBL26998671 | 0.84 | ROCK2 (0.37) | P2RX7ROCK2ROCK1 | |
| SCHEMBL27000337 | 0.83 | ATR (0.38) | ROCK2ATRATRIPROCK1CDC42BPA | |
| SCHEMBL27000760 | 0.82 | PRKAB2 (0.39) | P2RX7ROCK2ATRATRIP | |
| SCHEMBL27000362 | 0.81 | ROCK2 (0.38) | P2RX7ROCK2ATRATRIP | |
| SCHEMBL26998317 | 0.81 | ROCK2 (0.36) | ROCK2ATRATRIPROCK1CDC42BPA | |
| SCHEMBL26998315 | 0.80 | PIK3CD (0.44) | ROCK2ATRATRIP | |
| SCHEMBL26998091 | 0.80 | ROCK2 (0.43) | ROCK2ATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | P2RX7 253/4885ROCK2 1771/4885ATR 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.